Know Cancer

or
forgot password

Adrenal Scans With Radioiodine-Labeled Norcholesterol (NP-59)


N/A
N/A
N/A
Not Enrolling
Both
Adrenal Gland Neoplasms, Adrenal Malignancies, Abnormal Hormonal Secretions, Electrolytes Abnormalities

Thank you

Trial Information

Adrenal Scans With Radioiodine-Labeled Norcholesterol (NP-59)


To investigate the feasibility of using NP-59 to localize adrenal tumors and assess their
functions under the influence of pharmacological manipulations.


Inclusion Criteria:



- Patient with clinical and laboratory suspicions of hypersecretion of adrenal cortical
hormones

Exclusion Criteria:

- n/a

Type of Study:

Interventional

Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

To investigate the feasibility of using NP-59 to localize adrenal tumors and assess their functions under the influence of pharmacological manipulations.

Outcome Time Frame:

1 year

Safety Issue:

No

Principal Investigator

Neeta Pandit-Taskar, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center

Authority:

United States: Food and Drug Administration

Study ID:

77-030

NCT ID:

NCT00591643

Start Date:

July 1977

Completion Date:

March 2011

Related Keywords:

  • Adrenal Gland Neoplasms
  • Adrenal Malignancies
  • Abnormal Hormonal Secretions
  • Electrolytes Abnormalities
  • Adrenal tumors
  • Adrenal malignancies
  • abnormal hormonal secretions
  • electrolytes abnormalities
  • Imaging
  • Scanning
  • tumor localization
  • Congenital Abnormalities
  • Adrenal Gland Neoplasms
  • Neoplasms

Name

Location

Memorial Sloan-Kettering Cancer CenterNew York, New York  10021